JP2015509097A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509097A5 JP2015509097A5 JP2014552303A JP2014552303A JP2015509097A5 JP 2015509097 A5 JP2015509097 A5 JP 2015509097A5 JP 2014552303 A JP2014552303 A JP 2014552303A JP 2014552303 A JP2014552303 A JP 2014552303A JP 2015509097 A5 JP2015509097 A5 JP 2015509097A5
- Authority
- JP
- Japan
- Prior art keywords
- binding molecule
- binding
- molecule
- tmem30a
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100026772 Cell cycle control protein 50A Human genes 0.000 claims description 24
- 101000910814 Homo sapiens Cell cycle control protein 50A Proteins 0.000 claims description 24
- 239000013543 active substance Substances 0.000 claims description 18
- 208000012902 Nervous system disease Diseases 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261585039P | 2012-01-10 | 2012-01-10 | |
| US61/585,039 | 2012-01-10 | ||
| PCT/US2013/021041 WO2013106577A2 (en) | 2012-01-10 | 2013-01-10 | Enhancement of transport of therapeutic molecules across the blood brain barrier |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509097A JP2015509097A (ja) | 2015-03-26 |
| JP2015509097A5 true JP2015509097A5 (enExample) | 2016-02-12 |
| JP6247226B2 JP6247226B2 (ja) | 2017-12-13 |
Family
ID=47633561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552303A Expired - Fee Related JP6247226B2 (ja) | 2012-01-10 | 2013-01-10 | 血液脳関門を越える治療分子の輸送の向上 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9676849B2 (enExample) |
| EP (1) | EP2802606B1 (enExample) |
| JP (1) | JP6247226B2 (enExample) |
| KR (1) | KR102104686B1 (enExample) |
| CN (1) | CN104159922B (enExample) |
| AU (1) | AU2013207927B2 (enExample) |
| BR (1) | BR112014016887A2 (enExample) |
| CA (1) | CA2860579A1 (enExample) |
| CY (1) | CY1120419T1 (enExample) |
| DK (1) | DK2802606T3 (enExample) |
| EA (1) | EA201491346A1 (enExample) |
| ES (1) | ES2677111T3 (enExample) |
| HR (1) | HRP20180937T1 (enExample) |
| HU (1) | HUE039033T2 (enExample) |
| IL (1) | IL233246B (enExample) |
| LT (1) | LT2802606T (enExample) |
| MX (1) | MX350378B (enExample) |
| NZ (1) | NZ626620A (enExample) |
| PL (1) | PL2802606T3 (enExample) |
| PT (1) | PT2802606T (enExample) |
| SI (1) | SI2802606T1 (enExample) |
| TR (1) | TR201809743T4 (enExample) |
| WO (1) | WO2013106577A2 (enExample) |
| ZA (1) | ZA201404873B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6148729B2 (ja) | 2012-07-04 | 2017-06-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 共有結合している抗原−抗体結合体 |
| BR112016014945A2 (pt) | 2014-01-03 | 2018-01-23 | F. Hoffmann-La Roche Ag | conjugado, formulação farmacêutica e uso |
| KR20160104628A (ko) | 2014-01-03 | 2016-09-05 | 에프. 호프만-라 로슈 아게 | 이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도 |
| EP3089758B1 (en) | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
| MX375841B (es) * | 2014-03-06 | 2025-03-07 | Nat Res Council Canada | Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos. |
| KR102355310B1 (ko) * | 2014-03-06 | 2022-01-24 | 내셔날 리서치 카운실 오브 캐나다 | 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도 |
| JP6541235B2 (ja) * | 2014-03-06 | 2019-07-10 | ナショナル リサーチ カウンシル オブ カナダ | インスリン様成長因子１受容体特異的抗体及びそれらの使用 |
| JP6391318B2 (ja) * | 2014-06-27 | 2018-09-19 | 学校法人順天堂 | アルツハイマー病予防治療薬のスクリーニング法 |
| WO2016097315A2 (en) * | 2014-12-19 | 2016-06-23 | Medimmune Limited | Blood brain barrier transport molecules and uses thereof |
| AU2016210835B2 (en) | 2015-01-29 | 2021-01-21 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| JP7059494B2 (ja) * | 2016-07-06 | 2022-04-26 | ナショナル リサーチ カウンシル オブ カナダ | 血液脳関門を通過するヒト化抗体及びその使用 |
| WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| EP3551666A4 (en) | 2016-12-12 | 2020-07-29 | National Research Council of Canada | VARIANTS OF ANTIBODIES CROSSING THE HEMATOENCEPHALIC BARRIER AND THEIR USES |
| CA3052058A1 (en) | 2017-01-30 | 2018-08-02 | National Research Council Of Canada | Blood-brain barrier transmigrating compounds and uses thereof |
| US11453701B2 (en) | 2017-08-18 | 2022-09-27 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| JP7369127B2 (ja) * | 2017-12-28 | 2023-10-25 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体 |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| AU2019218786B2 (en) | 2018-02-07 | 2024-05-02 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
| WO2019246003A1 (en) * | 2018-06-18 | 2019-12-26 | Anwita Biosciences, Inc. | Anti-mesothelin constructs and uses thereof |
| EP3586860A1 (en) * | 2018-06-22 | 2020-01-01 | Universität Ulm | Complement inhibitors and uses thereof |
| US20210161993A1 (en) * | 2018-09-12 | 2021-06-03 | Pvp Labs Pte. Ltd. | Method for accelerated healing of burn wounds |
| CA3115071A1 (en) | 2018-10-04 | 2020-04-09 | University Of Rochester | Improvement of glymphatic delivery by manipulating plasma osmolarity |
| AU2019371814A1 (en) * | 2018-10-29 | 2021-06-17 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| CN113284553B (zh) * | 2021-05-28 | 2023-01-10 | 南昌大学 | 一种用于治疗药物成瘾的药物靶点结合能力测试方法 |
| AU2021476277A1 (en) | 2021-12-02 | 2024-06-06 | Linno Pharmaceuticals Inc. | Transferrin binding antibodies and use thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1166947A (en) | 1914-10-05 | 1916-01-04 | Paramount Hosiery Form Drying Company | Hosiery-finishing apparatus. |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US4849407A (en) | 1986-08-13 | 1989-07-18 | Zymogenetics, Inc. | Biologically active mosaic proteins |
| US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
| US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
| IL78444A (en) | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
| ATE143052T1 (de) | 1986-07-07 | 1996-10-15 | Centocor Inc | Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen |
| NO873164L (no) | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
| IL84285A (en) | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| CA1339445C (en) | 1986-11-12 | 1997-09-09 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and method of use |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990014425A1 (en) | 1989-05-22 | 1990-11-29 | Zymogenetics, Inc. | PDGF α-RECEPTOR |
| US5061786A (en) | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
| EP0939121B2 (de) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| CA2040099A1 (en) | 1990-05-01 | 1991-11-02 | Mariano Barbacid | Tyrosine kinase negative trkb |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5453491A (en) | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| JPH04334377A (ja) | 1990-12-31 | 1992-11-20 | Akzo Nv | 酸−不安定性リンカー分子 |
| EP0580751A1 (en) | 1991-04-19 | 1994-02-02 | Schering Corporation | Subunit of the human interleukin-3 receptor |
| US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
| US5348856A (en) | 1991-07-08 | 1994-09-20 | E. R. Squibb & Sons, Inc. | DNA encoding TRKC protein |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| US6451764B1 (en) | 1995-09-08 | 2002-09-17 | Genentech, Inc. | VEGF-related protein |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| AU729029B2 (en) | 1996-07-03 | 2001-01-25 | Genentech Inc. | Hepatocyte growth factor receptor agonists and uses thereof |
| US6159462A (en) | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
| EP0941120A4 (en) | 1996-11-05 | 2004-08-18 | Bristol Myers Squibb Co | BRANCHED PEPTIDLINKERS |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU762047B2 (en) | 1999-01-06 | 2003-06-19 | Genentech Inc. | Insulin-like growth factor (IGF) I mutant variants |
| JP3971108B2 (ja) | 1999-01-06 | 2007-09-05 | ジェネンテック・インコーポレーテッド | インシュリン様成長因子（ｉｇｆ）ｉ突然変異体 |
| SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
| US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
| US7943129B2 (en) * | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| DE60236861D1 (de) | 2001-04-26 | 2010-08-12 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2006083275A2 (en) | 2004-05-21 | 2006-08-10 | The Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
| AU2005307789A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| WO2007036021A1 (en) | 2005-09-27 | 2007-04-05 | National Research Council Of Canada | Blood-brain barrier epitopes and uses thereof |
| EP1986684A2 (en) * | 2006-02-15 | 2008-11-05 | ImClone Systems Incorporated | Functional antibodies |
| NZ581395A (en) | 2007-05-14 | 2012-08-31 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| JP5826194B2 (ja) * | 2010-03-03 | 2015-12-02 | アブリンクス ナームローゼ フェンノートシャップ | 二パラトープ性ａ−ベータ結合ポリペプチド |
| US8986689B2 (en) * | 2010-04-14 | 2015-03-24 | National Research Council Of Canada | Compositions and methods for brain delivery of analgesic peptides |
-
2013
- 2013-01-10 JP JP2014552303A patent/JP6247226B2/ja not_active Expired - Fee Related
- 2013-01-10 BR BR112014016887A patent/BR112014016887A2/pt not_active Application Discontinuation
- 2013-01-10 CN CN201380004989.7A patent/CN104159922B/zh not_active Expired - Fee Related
- 2013-01-10 NZ NZ626620A patent/NZ626620A/en not_active IP Right Cessation
- 2013-01-10 DK DK13702529.2T patent/DK2802606T3/en active
- 2013-01-10 ES ES13702529.2T patent/ES2677111T3/es active Active
- 2013-01-10 KR KR1020147018724A patent/KR102104686B1/ko not_active Expired - Fee Related
- 2013-01-10 WO PCT/US2013/021041 patent/WO2013106577A2/en not_active Ceased
- 2013-01-10 SI SI201331060T patent/SI2802606T1/en unknown
- 2013-01-10 US US14/370,828 patent/US9676849B2/en active Active
- 2013-01-10 PL PL13702529T patent/PL2802606T3/pl unknown
- 2013-01-10 HR HRP20180937TT patent/HRP20180937T1/hr unknown
- 2013-01-10 AU AU2013207927A patent/AU2013207927B2/en not_active Ceased
- 2013-01-10 PT PT137025292T patent/PT2802606T/pt unknown
- 2013-01-10 EA EA201491346A patent/EA201491346A1/ru unknown
- 2013-01-10 CA CA2860579A patent/CA2860579A1/en active Pending
- 2013-01-10 LT LTEP13702529.2T patent/LT2802606T/lt unknown
- 2013-01-10 EP EP13702529.2A patent/EP2802606B1/en active Active
- 2013-01-10 TR TR2018/09743T patent/TR201809743T4/tr unknown
- 2013-01-10 HU HUE13702529A patent/HUE039033T2/hu unknown
- 2013-01-10 MX MX2014008365A patent/MX350378B/es active IP Right Grant
-
2014
- 2014-06-19 IL IL233246A patent/IL233246B/en active IP Right Grant
- 2014-07-01 ZA ZA2014/04873A patent/ZA201404873B/en unknown
-
2018
- 2018-07-11 CY CY20181100721T patent/CY1120419T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509097A5 (enExample) | ||
| HRP20180937T1 (hr) | Poboljšavanje transporta terapijskih molekula kroz krvno-moždanu barijeru | |
| JP6817492B2 (ja) | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 | |
| AU2015279128B2 (en) | Multispecific antibody constructs | |
| JP6872181B2 (ja) | ＩｇＧ結合ペプチドによる抗体の特異的修飾 | |
| TWI886164B (zh) | 1價ccap生成物之製造方法 | |
| JP2017500018A5 (enExample) | ||
| JP2010539921A5 (enExample) | ||
| JP2009535021A5 (enExample) | ||
| JP2019522490A5 (enExample) | ||
| JP2012529891A5 (enExample) | ||
| JP2018537421A5 (enExample) | ||
| JP2013506411A5 (enExample) | ||
| HRP20200036T1 (hr) | Postupci liječenja tauopatije | |
| JP2017534296A5 (enExample) | ||
| JP2020500885A5 (enExample) | ||
| JP2010524849A5 (enExample) | ||
| JP2014519830A5 (enExample) | ||
| JP2010531140A5 (enExample) | ||
| JP2016524592A5 (enExample) | ||
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| JP2017514515A5 (enExample) | ||
| JP2021512159A5 (enExample) | ||
| JP2008521426A5 (enExample) | ||
| JP2008515889A5 (enExample) |